WELCOME WELCOME BACK WELCOME BACK HERE WELCOME BACK HERE EVERYONE. WELCOME BACK HERE EVERYONE. COULD WELCOME BACK HERE EVERYONE. COULD AN WELCOME BACK HERE EVERYONE. COULD AN ARTHRITIS WELCOME BACK HERE EVERYONE. COULD AN ARTHRITIS DRUG WELCOME BACK HERE EVERYONE. COULD AN ARTHRITIS DRUG BE WELCOME BACK HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A WELCOME BACK HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE TREATMENT HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR KOVIC? HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR KOVIC? NINETEEN ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR KOVIC? NINETEEN ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN ARTHRITIS DRUG BE A POSSIBLE TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN PATIENTS TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN PATIENTS TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN PATIENTS EXPERIENCE TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC TREATMENT FOR KOVIC? NINETEEN SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN DIEGO SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED SPECIFICALLY WHEN PATIENTS EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A PHASE EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A PHASE 3 EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. EXPERIENCE PNEUMONIA UC SAN DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING US DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING US NOW DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. OUT DIEGO HEALTH HAS LAUNCHED A PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. OUT TUOL PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. OUT TUOL PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. OUT TUOL MALHOTRA, PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR PHASE 3 CLINICAL TRIAL. AND JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR OF JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR OF JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR OF RESPIRATORY JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO JOINING US NOW IS DR. OUT TUOL MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE THE MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE MALHOTRA, PROFESSOR OF RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS.
RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS. RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS. GOOD RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS. GOOD MORNING RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, RESPIRATORY MEDICINE TO SHARE THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THANKS THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THANKS FOR THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE.
THE IMPORTANCE OF THESE TRIALS. GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD MORNING. GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD MORNING. GIVE GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD MORNING. GIVE US GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE NAME GOOD MORNING TO YOU, DOCTOR. THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE NAME OF THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE NAME OF THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE NAME OF THIS THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE NAME OF THIS TREATMENT. THANKS FOR BEING HERE. GOOD MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT THE MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT THE OUTCOME MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT THE OUTCOME IS MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT THE OUTCOME IS THAT MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE MORNING. GIVE US THE NAME OF THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING FOR THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG THIS TREATMENT. WHAT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS IN THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS IN FACT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS IN FACT A THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT THE OUTCOME IS THAT WE’RE ALL HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT THIS HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT THIS POINT HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT THIS POINT THERE HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A HOPING FOR AND IF THIS DRUG IS IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG CALLED IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG CALLED COUNSELORS IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG CALLED COUNSELORS A IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP IN FACT A VIABLE TREATMENT AT THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH WE’RE THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH WE’RE NOW THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO THIS POINT THERE IS A DRUG CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG THAT’S CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG THAT’S BEEN CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR CALLED COUNSELORS A MAP WHICH WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE BEING WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE BEING USED WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE BEING USED TO WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT WE’RE NOW STUDYING TO DRUG THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT ARTHRITIS THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT ARTHRITIS THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT ARTHRITIS AND THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT ARTHRITIS AND SOMETHING THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT ARTHRITIS AND SOMETHING CALLED THAT’S BEEN AROUND FOR WHILE BEING USED TO TREAT ARTHRITIS AND SOMETHING CALLED CYTOKINE BEING USED TO TREAT ARTHRITIS AND SOMETHING CALLED CYTOKINE BEING USED TO TREAT ARTHRITIS AND SOMETHING CALLED CYTOKINE STORM BEING USED TO TREAT ARTHRITIS AND SOMETHING CALLED CYTOKINE STORM CYTOKINE BEING USED TO TREAT ARTHRITIS AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE SYNDROME. AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE SYNDROME. AND AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE SYNDROME. AND WE AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT AND SOMETHING CALLED CYTOKINE STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT MAY STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT MAY STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT MAY HAVE STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT MAY HAVE SOME STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE STORM CYTOKINE RELEASE SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED PNEUMONIA SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED PNEUMONIA AS SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED PNEUMONIA AS WELL.
SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO SYNDROME. AND WE BELIEVE IT MAY HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE TRYING HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE TRYING TO HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT HAVE SOME VALUE COVERED PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PATIENTS PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PATIENTS AROUND PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD PNEUMONIA AS WELL. SO WE’RE TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD AND TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD AND TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD AND WE’RE TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD AND WE’RE ABOUT TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY TRYING TO ENROLL ABOUT 450 PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE STUDY PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 PATIENTS AROUND THE WORLD AND WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE YOU’VE WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT WE’RE ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THROUGH THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THROUGH THE THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN THE STUDY NOW. SO PHASE 3 WHERE YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. RIGHT. YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN YOU’VE BEEN ABOUT HALFWAY THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THE THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE THROUGH THE PROCESS, WHEN WILL WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS BECAUSE WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL WE. RIGHT. OH, IF IT CAN REDUCE THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, RIGHT? THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE THE INFLAMMATION IN THE LUNGS BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO GOALS.
BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO GOALS. ONE BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO GOALS. ONE IS BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO BECAUSE THAT’S THE GOAL HERE, RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO REDUCE RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO REDUCE RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO REDUCE INFLAMMATION RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO REDUCE INFLAMMATION FOR RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. RIGHT? WELL, THERE ARE TWO GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS THE GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS GOALS. ONE IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS TO INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS TO INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS TO REDUCE INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS TO REDUCE THE INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING INFLAMMATION FOR SURE. BUT PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING PATIENTS. PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING PATIENTS. PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING PATIENTS. SO PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING PATIENTS. SO WE’RE PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING PATIENTS. SO WE’RE LOOKING PERHAPS THE BIGGER GOAL IS TO REDUCE THE SUFFERING PATIENTS. SO WE’RE LOOKING FOR REDUCE THE SUFFERING PATIENTS. SO WE’RE LOOKING FOR REDUCE THE SUFFERING PATIENTS. SO WE’RE LOOKING FOR IMPROVEMENTS REDUCE THE SUFFERING PATIENTS. SO WE’RE LOOKING FOR IMPROVEMENTS IN REDUCE THE SUFFERING PATIENTS. SO WE’RE LOOKING FOR IMPROVEMENTS IN CLINICAL SO WE’RE LOOKING FOR IMPROVEMENTS IN CLINICAL SO WE’RE LOOKING FOR IMPROVEMENTS IN CLINICAL OUTCOMES SO WE’RE LOOKING FOR IMPROVEMENTS IN CLINICAL OUTCOMES THAT SO WE’RE LOOKING FOR IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS SO WE’RE LOOKING FOR IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T NEED IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH IMPROVEMENTS IN CLINICAL OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND ARE OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND ARE NOT OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS OUTCOMES THAT PATIENTS DON’T NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH OXYGEN.
NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH OXYGEN. SO NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING NEED RESPIRATORS AS MUCH AND ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING FOR ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING FOR ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING FOR CLINICAL ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN ARE NOT REQUIRING AS MUCH OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR CARE OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR CARE AND OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL OXYGEN. SO WE’RE LOOKING FOR CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO BETTER CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO BETTER AS CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO BETTER AS A CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF CLINICAL IMPROVEMENTS IN THEIR CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS TREATMENT. CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS TREATMENT. I CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS TREATMENT. I WAS CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS TREATMENT. I WAS READING CARE AND HOPEFULLY THEY’LL DO BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME PROMISING BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME PROMISING RESULTS BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME PROMISING RESULTS OF BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS BETTER AS A RESULT OF THIS TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG ON TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG ON PATIENTS TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG ON PATIENTS IN TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN TREATMENT. I WAS READING SOME PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU TELL PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU TELL US PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S PROMISING RESULTS OF THIS DRUG ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A RATHER ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A RATHER SMALL ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT ON PATIENTS IN CHINA. CAN YOU TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT IT’S TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT IT’S TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT IT’S SOME TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT IT’S SOME PROMISING TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. TELL US ABOUT THAT? THAT’S A RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU KNOW, RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU KNOW, THERE’S RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A RATHER SMALL STUDY BUT IT’S SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW STUDIES SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW STUDIES ON SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM SOME PROMISING RESULTS. YOU KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE BEEN KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS KNOW, THERE’S BEEN A FEW STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS IN STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA.
STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME STUDIES ON TURTLE ISM WHICH HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT IN HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT IN EUROPE HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR HAVE BEEN DONE IN ITALY AS WELL AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST A AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW AS IN CHINA. SOME DATA CAME OUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT 200 IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A IN EUROPE LAST WEEK OR ACTUALLY JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED TRIAL JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED TRIAL WHERE JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW JUST A FEW DAYS AGO. NOW ABOUT 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE NEED 200 PATIENTS IN A RANDOMISED TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE NEED FOR TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE NEED FOR TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE NEED FOR EITHER TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL TRIAL WHERE THEY DID SHOW SOME IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION OR IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION OR DEATH. IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION OR DEATH. IT IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION OR DEATH. IT WAS IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A IMPROVEMENTS IN THE NEED FOR EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL STUDIES EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL STUDIES ABOUT EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS EITHER MECHANICAL VENTILATION OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT IT OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT IT WAS OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND OR DEATH. IT WAS A SMALL STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE PUSHING STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE PUSHING ON STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE PUSHING ON WITH STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDIES ABOUT 200 PATIENTS BUT IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDY. IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDY.
IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDY. IT’S IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDY. IT’S PREMATURE IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO IT WAS PROMISING AND WE’RE PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW CONCLUSIONS. PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW CONCLUSIONS. SO PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY PUSHING ON WITH THIS STUDY. IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY MUCH IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY MUCH IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING IT’S PREMATURE TO DRAW CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. BUT CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. BUT SO CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. CONCLUSIONS. SO WE’RE VERY MUCH FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. WE FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. WE FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. WE HAVE FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED FOCUSED ON COMPLETING THIS STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE WHERE STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE WHERE WE STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW STUDY. BUT SO FAR SO GOOD. WE HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH TREATMENT HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH TREATMENT IS HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER.
HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND HAVE WHAT’S CALLED EQUIPOISE WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WE’RE WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WE’RE PUSHING WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WE’RE PUSHING ON WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY WHERE WE DON’T KNOW WHICH TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY AND TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY AND TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY AND COMPLETE TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY AND COMPLETE THE TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY TREATMENT IS BETTER. AND SO WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S ONGOING. WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S ONGOING. HOW WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S ONGOING. HOW DOES WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S ONGOING. HOW DOES TOTAL WE’RE PUSHING ON TO TRY AND COMPLETE THE STUDY THAT’S ONGOING. HOW DOES TOTAL VISIT COMPLETE THE STUDY THAT’S ONGOING. HOW DOES TOTAL VISIT COMPLETE THE STUDY THAT’S ONGOING. HOW DOES TOTAL VISIT MAB COMPLETE THE STUDY THAT’S ONGOING. HOW DOES TOTAL VISIT MAB DIFFER COMPLETE THE STUDY THAT’S ONGOING. HOW DOES TOTAL VISIT MAB DIFFER FROM ONGOING. HOW DOES TOTAL VISIT MAB DIFFER FROM ONGOING. HOW DOES TOTAL VISIT MAB DIFFER FROM THE ONGOING. HOW DOES TOTAL VISIT MAB DIFFER FROM THE HYDROCHLORIC ONGOING. HOW DOES TOTAL VISIT MAB DIFFER FROM THE HYDROCHLORIC WHEN ONGOING. HOW DOES TOTAL VISIT MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE HEARD MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE HEARD SO MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT MAB DIFFER FROM THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO SOCIALISM THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO SOCIALISM AB THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO SOCIALISM AB A THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK THE HYDROCHLORIC WHEN WE’VE HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING CALLED HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING CALLED AISLE HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX HEARD SO MUCH ABOUT TO SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE OF SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE OF THE SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE SOCIALISM AB A BLOCK SOMETHING CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD THAT CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD THAT IS CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD THAT IS RELATED CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO CALLED AISLE SIX AISLE SIX ONE OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION AND OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION AND THERE’S OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION AND THERE’S AN OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE OF THE PROTEINS IN THE BLOOD THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX RECEPTOR THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX RECEPTOR THAT THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX RECEPTOR THAT THIS THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX RECEPTOR THAT THIS DRUG THAT IS RELATED TO INFLAMMATION AND THERE’S AN AISLE SIX RECEPTOR THAT THIS DRUG IS AND THERE’S AN AISLE SIX RECEPTOR THAT THIS DRUG IS AND THERE’S AN AISLE SIX RECEPTOR THAT THIS DRUG IS SPECIFICALLY AND THERE’S AN AISLE SIX RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING HYDROXIDE RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A RECEPTOR THAT THIS DRUG IS SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG THAT’S SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR MALARIA SPECIFICALLY TARGETING HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR MALARIA AND HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR MALARIA AND HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR MALARIA AND RHEUMATOID HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS HYDROXIDE CHLOROQUINE IS A DRUG THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER IT’S THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED THAT’S USED FOR MALARIA AND RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA RHEUMATOID ARTHRITIS WHETHER IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO NOT IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO NOT LOOK IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING IT’S EFFECTIVE FOR COVERED WE DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT THERE’S DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT THERE’S OVER DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT THERE’S OVER 90 DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING DON’T KNOW. SO FAR THE DATA DO NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES ON NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES ON HOW NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND NOT LOOK VERY PROMISING BUT THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE.
THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. SO THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. SO MAYBE THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. THERE’S OVER 90 ONGOING STUDIES ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. WE ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. WE ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. WE TALK ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. WE TALK ABOUT ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE ON HOW DRUGS AND CHLOROQUINE. SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL TRIALS SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL TRIALS THE SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL TRIALS THE PHASE SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND SO MAYBE TIME WILL TELL. WE TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL THESE TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL THESE THINGS. TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO TALK ABOUT THESE CLINICAL TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR VIEWERS TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR VIEWERS AT TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR VIEWERS AT HOME, TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE TRIALS THE PHASE 3S AND ALL THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE TRIALS THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE TRIALS THE THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE THESE THINGS. BUT TO OUR VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO IMPORTANT? VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO IMPORTANT? WELL, VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE VIEWERS AT HOME, WHY ARE THESE TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST GIVE TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF TRIALS THE PROCESS HERE SO IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE JUST IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK IMPORTANT? WELL, SO IF WE JUST GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS MIGHT GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS MIGHT WORK GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS MIGHT WORK OR GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT GIVE DRUGS HAPHAZARDLY, IF WE JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, WE’LL JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. JUST SAY WELL, I THINK THIS MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE DON’T MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, MIGHT WORK OR THAT MIGHT WORK, WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT DOESN’T.
WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE WE’LL NEVER LEARN THE TRUTH. WE DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN NEW DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN NEW YORK DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE DON’T KNOW WHAT WORKS, WHAT DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST COAST DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST COAST ARE DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST COAST ARE GETTING DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS DOESN’T. MANY OF THE PATIENTS IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS THESE IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS THESE IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS THESE THERAPIES IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS THESE THERAPIES SORT IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS THESE THERAPIES SORT OF IN NEW YORK AND ON THE EAST COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY MEANING COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY MEANING WE COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW COAST ARE GETTING LOTS THESE THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THEY’RE THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THEY’RE WORKING THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THEY’RE WORKING OR THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT THERAPIES SORT OF EMPIRICALLY MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT BUT MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT BUT MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT BUT WE’LL MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT BUT WE’LL NEVER MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY MEANING WE DON’T KNOW IF THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THE THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THE TRUTH. THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THE TRUTH. AND THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S THEY’RE WORKING OR NOT BUT WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE ISSUE. WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS WE’LL NEVER REALLY LEARN THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE DRUGS THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE DRUGS HAVE THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND THE TRUTH. AND SO THAT’S ONE ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND SO ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND SO ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND SO LIKE ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT ISSUE. SECOND ISSUE IS THESE DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN MEDICINE, DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN MEDICINE, THIS DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN MEDICINE, THIS RISK DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND DRUGS HAVE SIDE EFFECTS AND SO LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT IF LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT IF YOU LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT IF YOU JUST LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE LIKE EVERY TREATMENT IN MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS NILLY MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER MEDICINE, THIS RISK AND BENEFIT IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE KNOW IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND IF YOU JUST GONNA GIVE THINGS NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN THE NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN THE THIRD NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE NILLY YOU’LL YOU’LL NEVER QUITE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE THE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE THE STORIES KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS.
KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS. SO KNOW WHAT’S WORKING. AND THEN THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS. SO FOR THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS. SO FOR THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS. SO FOR EXAMPLE, THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE THE THIRD ISSUE IS WE DEPLETE THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE AND THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE AND THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE AND HYDROXIDE THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE THE STORIES THESE DRUGS. SO FOR EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE USED EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE USED EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE USED TO EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE USED TO TREAT EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID EXAMPLE, CHLOROQUINE AND HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS AND HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS AND LUPUS HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT HYDROXIDE CHLOROQUINE ARE USED TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT KINDS TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT KINDS TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT KINDS OF TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT KINDS OF MALARIA TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES TO TREAT RHEUMATOID ARTHRITIS AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND THE AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND THE WORLD. AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS AND LUPUS AND DIFFERENT KINDS OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER HALF OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER HALF A OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER HALF A MILLION OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER OF MALARIA ILLNESSES AROUND THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND IF THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND IF WE THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS THE WORLD. MALARIA KILLS OVER HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR OUR HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE HALF A MILLION PEOPLE PER YEAR. AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A RISK AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A RISK FOR AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A RISK FOR THOSE AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AND IF WE LOSE THOSE DRUGS FOR OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS WELL.
OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS WELL. THAT OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS WELL. THAT IS OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS WELL. THAT IS TO OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY OUR PATIENTS, THERE’LL BE A RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING THAT RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING THAT DRUG RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING RISK FOR THOSE PATIENTS AS WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING TO WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING TO WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING TO HAVE WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE WELL. THAT IS TO SAY DEPLETING THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN KNOW THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR THAT DRUG STORE IS GOING TO HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR NOT HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR NOT HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR NOT UNCOVERED. HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN HAVE CONSEQUENCES. WE DON’T EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING THIS. EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE EVEN KNOW IF IT WORKS OR NOT UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT OF UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT OF THE UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY UNCOVERED. YOU’VE BEEN STUDYING THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE.
THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW FAR THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK THIS. YOU’RE AT THE FOREFRONT OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO A OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 OF THE MEDICAL COMMUNITY HERE. HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT THIS HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION HOW FAR AWAY DO YOU THINK WE ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS DONE ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS DONE BY ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS DONE BY THE ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS DONE BY THE END ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS DONE BY THE END OF ARE TO A VACCINE FOR KOBE 19 AT THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS CALENDAR THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS CALENDAR YEAR THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS CALENDAR YEAR THERE’LL THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS CALENDAR YEAR THERE’LL BE THIS POINT? SO DISCUSSION IS DONE BY THE END OF THIS CALENDAR YEAR THERE’LL BE A DONE BY THE END OF THIS CALENDAR YEAR THERE’LL BE A DONE BY THE END OF THIS CALENDAR YEAR THERE’LL BE A VACCINE DONE BY THE END OF THIS CALENDAR YNature’s Way Sambucus Black Elderberry Gummies with Vitamin C and Zinc, 60 Gummies
Source: CBS 8 San Diego
Comments
Post a Comment